What is JadeBio?
JadeBio operates at the intersection of advanced mass spectrometry and biological research, providing specialized proteomics services that are critical for modern drug development. The company utilizes proprietary sample preparation methods to achieve deep proteome coverage, enabling researchers to perform precise protein quantitation and identify complex post-translational modifications. Their service portfolio, which includes Selective Reaction Monitoring and comprehensive proteome-wide profiling, serves as a foundational resource for organizations engaged in biomarker discovery and therapeutic research. By offering high-fidelity antibody sequencing and characterization, JadeBio has established itself as a vital partner for pharmaceutical and biotech entities seeking to navigate the complexities of the human proteome.
How much funding has JadeBio raised?
JadeBio has raised a total of $49K across 1 funding round:
Debt
$49K
Debt (2021): $49K with participation from PPP
Key Investors in JadeBio
PPP
Public-Private Partnership
What's next for JadeBio?
With the recent infusion of capital, JadeBio is expected to scale its mass spectrometry infrastructure to meet the rising demand for high-throughput biological analysis. The strategic focus will likely shift toward enhancing their proprietary platform capabilities to support larger-scale clinical trials and more complex therapeutic research initiatives. As the industry moves toward personalized medicine, JadeBio's ability to provide accurate, scalable protein data will be a key driver of their long-term growth trajectory. The company is well-positioned to capitalize on the increasing reliance on proteomics in drug discovery, potentially expanding its footprint in both academic and commercial research markets through continued technological innovation and service diversification.
See full JadeBio company page
